Market Scenario 

The Global Opioid Withdrawal Syndrome (OWS) Market is estimated to witness a rise in revenue from US$ 1,068.3 Mn in 2021 to US$ 2,633.4 Mn by 2030. The market is registering a CAGR of 10.4% during the forecast period 2022-2030.

Opioids are a class of drugs that are commonly prescribed to treat pain. Opioids include both opiates (drugs derived from the opium poppy, including morphine, codeine, heroin, and opium) and synthetic opioids like hydrocodone, oxycodone and methadone, which have similar effects. When the use of opiate drugs is stopped, it may produce several withdrawal symptoms and collectively these symptoms are called Opiate Withdrawal Syndrome (OWS). Opiate withdrawal symptoms may range from mild to severe, depending on how dependent the individual is on an opioid drug. Also, each opiate drug has a unique half-life as a result, withdrawal symptoms may start at different times, depending on the drug and method in which it is taken. Moreover, the use of opioids leads to suppression of brain stem function. The brain stem tries to overcome this suppression by increasing output, sudden stop of opioid use causes ‘fight or flight’ output from the brainstem and leads to the symptoms of OWS. 

Clinical Features of Opioid Withdrawal - detected & monitored using the Opioid Withdrawal Scale (OWS)

Physical signs/symptoms- 

• Lacrimation, rhinorrhea, yawning
• Dilated pupils, nausea/vomiting
• Diaphoresis, chills, piloerection, mild tachycardia and/or hypertension
• Myalgias, abdominal cramps, diarrhea

Psychological symptoms- 

• Anxiety and dysphoria
• Craving for opioids
• Restlessness, insomnia, fatigue

The major factor responsible for the growth of the global opioid withdrawal syndrome (OWS) market includes increasing cases of opioid addiction and increasing engagement by private and public institutions. In today’s scenario, the general population suffers from a wide range of severe and chronic diseases including cardiovascular, pain arising from injuries and other conditions. These diseases often cause chronic pain amongst the patients that are managed with the consumption of painkillers, mostly opioids. While the pain reduces, there is a greater chance that the patient may get addicted to these drugs. Moreover, increasing involvement of private and government institute in opioid withdrawal syndrome therapy is the key factor for the growth of the market. However, adverse side effects of opioids are expected to hinder the market growth during the forecast period.

Report Summary

The study of the Global Opioid Withdrawal Syndrome (OWS) Market considers various market determinants, drivers and challenges of the market. The report discusses the analysis of the opioid withdrawal syndrome industry for the period 2018-2030, where the base year is 2021 and the forecast period is 2022-2030. The market estimates are presented in terms of value (US$ Mn). 

The report provides a detailed analysis of the Global Opioid Withdrawal Syndrome (OWS) Market across 26 Chapters and 159 pages. The report includes data presentation across 9 tables and 47 statistical figures. The subsequent section provides details of the market analysis based on different segments such as therapy and country. 

SWOT Analysis of the Global Opioid Withdrawal Syndrome (OWS) Market 

STRENGTHS 

• Growing prevalence of chronic diseases
• New opioids formulation to reduce the risk of abuse
• Rise in demand for pain management

WEAKNESSES 

• Misuse of opioid prescription led to increase in number of deaths
• Lawsuits are filed against manufacturers due to increase in epidemic

OPPORTUNITIES

• Increase in demand for non-opioids drugs for the therapy of opioid withdrawal syndrome
• Increasing government funding in drug testing
• Growing awareness for withdrawal of opioids

THREATS

• The loss of patents exclusivity and the entrance of numerous generic players in the OSW market have led to decrease in share of key players.

Key Takeaways from the Global Opioid Withdrawal Syndrome (OWS) Market Report

• Based on therapy, buprenorphine is estimated to have the highest market share in 2021 as it has long half-life, high potency, and ceiling effect’ for both euphoric sensation and adverse effects make it an optimal treatment alternative for patients presenting to the ED with opioid withdrawal. Moreover, the lucemyra (lofexidine) segment is expected to project the highest CAGR during the forecast period.
• On the basis of country, US is the dominating region in the opioid withdrawal syndrome (OWS) market in 2021 and is also expected to project the highest CAGR during the forecast period owing to increasing prevalence of chronic diseases, which is leading to the rise in the adoption of opioids for pain management.

Strategic Outlook of the key players in the Global Opioid Withdrawal Syndrome (OWS) Market

• The US Worldmeds LLC, company targets to strengthens its research and development, along with the focusing to expand its global presence to increase the revenue source. It also aims to collaborate with the governments to grow its reach and strengthen its capabilities worldwide.
• The Aphios Corporation, company focused on increasing the partnerships/collaborations with the healthcare industry experts as well as other multinational and emerging biotechnology companies. It also collaborates with strategic investors and corporate partners to further the development and commercialization of its products.
• The Chiesi Farmaceutici S.p.A., company focuses on the research and development investments to clear its wide number of preclinical products. Also, it aims to target government authorities to further enhance its global offering in the end-use market. It also advancing a program for a novel therapeutic for the treatment of neonatal opioid withdrawal syndrome (NOWS).
• The Titan Pharmaceuticals, Inc. company focuses to reduce the complexity of its distribution system to improve its ability to commercialize Probuphine. Also, it continues its focus to provide REMS- related support to healthcare providers with patients in active treatment with Probuphine.

Proposed Guidelines for OWS

• In March 2016, the U.S. Department of Health and Human Services Centers for Disease Control and Prevention, or the CDC issued guidelines for prescribing opioids for chronic pain.
• CDC developed and published the CDC Guideline for Prescribing Opioids for chronic pain to provide recommendations for the prescribing of opioid pain medication for patients 18 and older in primary care settings. Recommendations focus on the use of opioids in treating chronic pain.
• The guidelines advocate use of non-pharmacologic therapy and nonopioid pharmacologic therapy as first line therapy for chronic pain. When starting opioid therapy for chronic pain, clinicians are advised to prescribe immediate-release opioids instead of extended-release/long-acting or ER/LA, opioids and to prescribe the lowest effective dosage.
• Clinicians were directed to reassess patient’s medication needs when considering doses of 50 morphine milligram equivalents or MME or greater and should avoid increasing total daily doses to 90 MME or greater.
• A sharp reduction in prescriptions among primary care physicians and an increase among pain specialists are evidence of the shift in prescribing and in the dynamics of pain treatment.

Competitive Landscape

The key players in the Global Opioid Withdrawal Syndrome (OWS) Market are US Worldmeds LLC, Aphios Corporation, Chiesi Farmaceutici S.p.A., Titan Pharmaceuticals, Inc., BioDelivery Sciences International, Inc., Alkermes and Indivior PLC among others. Through extensive research, it is found that big players have adopted various competitive strategies such as mergers & acquisitions in order to have a grip of emerging market. Furthermore, leading companies are expanding their geographical boundaries by acquiring small brands and domestic companies.

Segmentation Overview 

Global Opioid Withdrawal Syndrome (OWS) Market is segmented based on therapy and country. The industry trends in the global opioid withdrawal syndrome (OWS) market are sub-divided into different categories in order to get a holistic view of the global marketplace. 

Following are the different segments of the Global Opioid Withdrawal Syndrome (OWS) Market:

By Therapy segment of the Global Opioid Withdrawal Syndrome (OWS) Market is sub-segmented into:

• Lucemyra (Lofexidine)
• Methadone
• Buprenorphine
• Naltrexone
• Others (Britlofex, Masimo Bridge, etc.)

By Country segment of the Global Opioid Withdrawal Syndrome (OWS) Market is sub-segmented into:

• US
• EU-5
  • UK
  • Germany
  • France
  • Italy
  • Spain
• Japan